AMT-130 and HTT-Lowering Therapies: Lessons from Preclinical Huntington's Disease Models

On November 2, 2026, uniQure announced that the U.S. Food and Drug Administration (FDA) had accepted its Biologics License Application (BLA) for AMT-130 (ifezuntirgene inilparvovec), an investigational AAV5 gene therapy for Huntington's disease (HD). Submitted under the accelerated approval pathway, the application received Priority Review, with a May 1, 2027 target action date and an advisory committee meeting tentatively planned ^[1].

For a disease with a known genetic cause but no approved disease-modifying treatment, this is an important milestone. It also brings a central translational challenge into focus: connecting sustained huntingtin lowering with meaningful preservation of function. AMT-130's development illustrates how clinical observations and disease-relevant animal models contribute different parts of that evidence.

AMT-130 Clinical Results and the Path to FDA Priority Review

AMT-130 delivers an engineered microRNA targeting human HTT through MRI-guided, convection-enhanced administration into the striatum. The treatment is designed to provide prolonged suppression after a single procedure, lowering both mutant and wild-type huntingtin ^[1].

Figure 1. Mechanism of mutant huntingtin production and its suppression by AMT-130 ^[2].

Its regulatory path has been uneven. According to uniQure, FDA guidance in November 2024 indicated that Phase I/II results compared with natural history controls could support an accelerated approval filing. Following an October 2025 pre-BLA meeting, however, the company reported that the agency no longer appeared to consider that evidence adequate. In June 2026, further discussions reopened the submission pathway ^[3,4].

The underlying issue is the interpretation of a small, externally controlled efficacy dataset. In the original 36-month analysis, 12 high-dose participants showed a mean cUHDRS change of −0.38, compared with −1.52 in propensity score-matched Enroll-HD controls—75% less decline (P=0.003). Total Functional Capacity (TFC) decline was 60% lower (P=0.033), and mean cerebrospinal fluid neurofilament light chain (NfL) remained below baseline ^[5].

Later findings added both support and uncertainty. An updated 36-month analysis of 15 high-dose participants showed 80% less cUHDRS decline (nominal P=0.005). At 48 months, the difference was 44% and not statistically significant (P=0.144), while TFC decline remained 61% lower (nominal P=0.008) ^[6]. These results support continued investigation but leave the durability and magnitude of benefit unresolved.

Figure 2. AMT-130 high-dose slowed clinical disease progression versus a propensity-matched external control (Enroll-HD) at Month 48 ^[6].

The U.S. study initially included a randomized sham-procedure group, but the long-term efficacy claim rests on external controls. Matching cannot remove unmeasured confounding or all differences in assessment. The planned confirmatory trial will therefore randomize approximately 200 patients to AMT-130 or standard of care, with TFC at 36 months as its primary endpoint ^[1].

How Preclinical Models Support HTT-Lowering Therapies

These uncertainties make the mechanistic evidence important, without making it a substitute for controlled clinical confirmation. Animal studies can establish whether the vector reaches relevant brain regions, lowers its intended target, maintains activity over time, and alters disease-related pathology or function.

For HTT-lowering therapies, this requires more than demonstrating reduced protein abundance. Researchers need to relate suppression to downstream effects while examining the consequences of lowering normal huntingtin. Dose, distribution, disease stage, and model genetics all influence that interpretation.

Expanded-polyglutamine, or polyQ, knock-in mice offer a useful framework. By introducing an expanded CAG tract into the endogenous Htt locus, these models place the disease-associated mutation within its genomic context, enabling investigation of molecular pathology as it develops over time ^[7].

PolyQ Knock-In Mouse Models for Huntington's Disease Research

Q140, HdhQ150, and Q175 belong to this broader model family, but their designs differ. The historical HdhQ150 line contains an expanded repeat in mouse Htt, whereas Q140 incorporates human exon 1 sequence. Q175 arose through repeat expansion in the Q140 lineage ^[7].

These distinctions affect experimental outcomes. In a controlled comparison using homozygous mice on a standardized C57BL/6J background, Q140 mice exhibited earlier behavioral abnormalities and striatal HTT aggregation than HdhQ150 mice. The difference was associated with greater incomplete HTT splicing and production of the pathogenic exon 1 protein ^[7].

Figure 3. Genomic structures and protein sequence of the genetically modified Htt locus of Q140 and HdhQ150 knock-in mice ^[7].

For therapeutic development, this makes the engineered sequence as important as repeat length. A human sequence-directed agent must recognize the model's target site, while studies of transcript processing require the relevant exon–intron architecture. The “Q” designation alone cannot establish suitability for either application.

AMT-130's Q175 experiments demonstrate the practical value of this approach. Following a single bilateral striatal administration, AAV5-miHTT produced dose-dependent mutant HTT lowering and reduced aggregate accumulation in the striatum and cortex 12 months later ^[8]. This established durable target engagement and a downstream pathological effect in an endogenous-locus model.

However, the heterozygous Q175 mice did not show sufficiently robust motor deficits in that experiment to assess functional rescue ^[8]. The result highlights the importance of matching the model to the endpoint: a strong system for molecular pharmacology may require complementary evidence for functional efficacy.

Figure 4. Sustained mutant HTT protein lowering and changes in HTT aggregate burden following AAV5-miHTT treatment in Q175 knock-in mice, measured 12 months after administration ^[8].

Other models supplied that evidence. R6/2 transgenic mice showed improved motor performance and survival, while humanized Hu128/21 transgenic mice supported assessment of human mutant and wild-type HTT suppression alongside striatal volume and cognition ^[8,9]. Large-animal studies addressed delivery and tolerability; notably, target-sequence mismatch prevented endogenous HTT lowering in the non-human primate study ^[10].

Cyagen's hHTT-Q150 Mouse Model: Genetic Design and Phenotypic Validation

The same experimental logic informs the use of Cyagen's hHTT-Q150(FVB) mouse (C001874). This model introduces a human HTT sequence containing 150 CAG repeats into exon 1 of mouse Htt on an FVB/NJCya background. Heterozygous animals are viable and fertile. Its design places it within the expanded-polyQ knock-in approach, although it should not be equated with either historical HdhQ150 or the Q175 line used in AMT-130 studies. In addition to the FVB-background model, Cyagen offers HTT mouse models on C57BL/6 (B6) and mixed B6;FVB backgrounds, providing additional options for HD research.

Cyagen has also generated phenotypic characterization data across several ages, providing an experimental basis beyond the allele design. Cyagen's publicly available validation data reports reduced rotarod latency at three months, with impairment persisting at six months. Male mice showed significantly reduced grip strength at six months, whereas no significant grip-strength changes were reported at two or three months.

At 14 months, both male and female hHTT-Q150(FVB) mice showed significantly reduced grip strength compared with wild-type controls. Rotarod performance was significantly impaired in males, while the difference in females did not reach statistical significance. Open-field testing showed reduced locomotor distance in both sexes. Center time was significantly reduced in males, whereas the difference in females was not statistically significant. These findings indicate age-associated motor and behavioral alterations, with some outcomes showing sex-dependent differences.

Together, these observations document age-associated motor and behavioral abnormalities. Center-time changes should be interpreted alongside locomotor activity rather than treated as an isolated measure of anxiety.

Figure 5. The grip strength, rotarod, and open field analysis of hHTT-Q150(FVB) mice at 14 months.

These data can help researchers select treatment windows and functional endpoints for preclinical studies. Pairing behavioral measurements with regional HTT quantification and pathological assessment would allow a program to test whether target engagement accompanies changes in disease-related outcomes. For sequence-directed therapies, the humanized interval and binding-site compatibility should be confirmed before study initiation.

Table 1. Research applications and key considerations for selected mouse models of Huntington's disease.

AMT-130's progress underscores why this connection matters. Clinical studies determine whether patients benefit; preclinical models establish where a therapy acts and how its biological effects relate to disease. Combining a defined polyQ knock-in design with age-specific characterization provides a practical foundation for building that translational evidence.

👉 [Explore Cyagen’s Huntington’s Disease Models and CRO Services]

👉 [Consult with Our Experts to Design Your Next High-Impact Project]

References

[1] uniQure Inc. uniQure announces FDA acceptance and priority review of the biologics license application for ifezuntirgene inilparvovec for the treatment of Huntington’s disease [Internet]. GlobeNewswire; 2026 Nov 2 [cited 2026 Nov 5].

[2] Wheeler E. A turning point in Huntington’s disease treatment: AMT-130 gene therapy. UCL Science Magazine [Internet]. 2026 Feb 3 [cited 2026 Nov 5].

[3] uniQure Inc. uniQure provides regulatory update on AMT-130 for Huntington’s disease [Internet]. GlobeNewswire; 2026 Mar 2 [cited 2026 Nov 5].

[4] uniQure N.V. uniQure announces submission of biologics license application for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease [Internet]. uniQure N.V.; 2026 Sep 2 [cited 2026 Nov 5].

[5] uniQure N.V. uniQure announces positive topline results from pivotal Phase I/II study of AMT-130 in patients with Huntington’s disease [Internet]. uniQure N.V.; 2025 Sep 24 [cited 2026 Nov 5].

[6] uniQure N.V. Phase I/II ifezuntirgene inilparvovec (AMT-130) Huntington’s disease program update [Internet]. uniQure N.V.; 2026 Sep 29 [cited 2026 Nov 5].

[7] Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, Bove NH, Lemesre V, Lerner RP, Zeitlin SO, Howland D, Neueder A, Landles C, Bates GP, Chesselet MF. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene. J Neurosci Res. 2019 Dec;97(12):1590-1605. doi: 10.1002/jnr.24493. Epub 2019 Jul 7. PMID: 31282030; PMCID: PMC6801054.

[8] Spronck EA, Brouwers CC, Vallès A, de Haan M, Petry H, van Deventer SJ, Konstantinova P, Evers MM. AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models. Mol Ther Methods Clin Dev. 2019 Mar 16;13:334-343. doi: 10.1016/j.omtm.2019.03.002. PMID: 30984798; PMCID: PMC6446047.

[9] Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020 Jan 10;48(1):36-54. doi: 10.1093/nar/gkz976. PMID: 31745548; PMCID: PMC7145682.

[10] Spronck EA, Vallès A, Lampen MH, Montenegro-Miranda PS, Keskin S, Heijink L, Evers MM, Petry H, Deventer SJV, Konstantinova P, Haan M. Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology. Brain Sci. 2021 Jan 20;11(2):129. doi: 10.3390/brainsci11020129. PMID: 33498212; PMCID: PMC7908995.